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Abstract
Background: Glypican 3 (GPC3) is a member of the family of glypican heparan sulfate proteoglycans (HSPGs). The
GPC3 gene may play a role in controlling cell migration, negatively regulating cell growth and inducing apoptosis.
GPC3 is downregulated in several cancers, which can result in uncontrolled cell growth and can also contribute to
the malignant phenotype of some tumors. The purpose of this study was to analyze the mechanism of action of
the GPC3 gene in clear cell renal cell carcinoma.
Methods: Five clear cell renal cell carcinoma cell lines and carcinoma samples were used to analyze GPC3 mRNA
expression (qRT-PCR). Then, representative cell lines, one primary renal carcinoma (786-O) and one metastatic renal
carcinoma (ACHN), were chosen to carry out functional studies. We constructed a GPC3 expression vector and
transfected the renal carcinoma cell lines, 786-O and ACHN. GPC3 overexpression was analyzed using qRT-PCR and
immunocytochemistry. We evaluated cell proliferation using MTT and colony formation assays. Flow cytometry was
used to evaluate apoptosis and perform cell cycle analyses.
Results: We observed that GPC3 is downregulated in clear cell renal cell carcinoma samples and cell lines compared
with normal renal samples. GPC3 mRNA expression and protein levels in 786-O and ACHN cell lines increased after
transfection with the GPC3 expression construct, and the cell proliferation rate decreased in both cell lines following
overexpression of GPC3. Further, apoptosis was not induced in the renal cell carcinoma cell lines overexpressing GPC3,
and there was an increase in the cell population during the G1 phase in the cell cycle.
Conclusion: We suggest that the GPC3 gene reduces the rate of cell proliferation through cell cycle arrest during the
G1 phase in renal cell carcinoma.
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Background
Renal cell carcinoma (RCC) is the most lethal urological
disease [1] and is responsible for 3% of all malignant neo-
plasms [2]. The incidence of RCC has been increasing
over the last few decades [3] due to advances in early de-
tection of renal tumors provided by ultrasound, computed
tomography and magnetic resonance imaging [4-6].
RCC is a heterogeneous histological disease, and clear
cell renal cell carcinoma (CCRCC) is the most common
histological subtype, making up approximately 75-80%
of the cases of renal tumors [1,7]. Renal cell carcinoma
is diagnosed in the advanced stage of the disease in 25%
of patients [8]. Although nephrectomy and radiotherapy
are effective, 30% of patients develop metastatic disease
after treatment, with a median survival period of one
year [7,9].
The occurrence of RCC is usually sporadic, although
genetic syndromes can cause a familial pattern of inherit-
ance. For example, Von–Hippel Lindau disease, which is as-
sociated with mutations and inactivation of the VHL gene
[10], is correlated with the occurrence of clear cell renal cell
carcinoma [11]. Therefore, it is important to identify genes
associated with CCRCC and to better understand their
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possible mechanisms of action in renal tumor cells. Sev-
eral studies have identified genes differentially expressed
in clear cell renal cell carcinoma and normal renal samples
[9,12]. One of these genes is GPC3, which is decreased in
clear cell renal cell carcinoma [9].
Glypican 3 (GPC3), which is located on the human X
chromosome (Xq26), is a member of the heparan sulfate
proteoglycan (HSPG) family [13,14]. This protein can
bind to the surface of the cell membrane via glycosyl-
phosphatidylinositol (GPI) anchorage [15]. GPC3 plays
important roles in cell growth regulation, proliferation,
differentiation, migration and apoptosis [16,17]. It is dif-
ferentially expressed in some tumor types – in hepatocel-
lular carcinoma and melanoma, GPC3 is highly expressed
[18]; however, its expression is reduced in ovarian and
breast cancer [19,20], a finding which suggests that GPC3
may be involved in tumor development [21]. The GPC3
gene is considered a potential molecular marker in hepa-
tocellular carcinoma [22] and may act as a tumor suppres-
sor in the ovary [19].
In the present study, we investigated the mechanisms
of action of GPC3 in renal cell carcinoma using colony
formation, cell proliferation, cell cycle progression and
apoptosis assays to assess the potential role of GPC3 in
this type of cancer.
Methods
Clear cell renal cell carcinoma samples
Thirty-five clear cell renal cell carcinoma samples and
two normal renal fresh-frozen tissue samples were ob-
tained from the Tumor Bank from the Pio XII Foundation/
IBILCE-UNESP, Sao Paulo, Brazil. The use of patient-
derived material was approved by the Research Ethics
Committee of the Tumor Bank from the Pio XII
Foundation/IBILCE-UNESP, Sao Paulo, Brazil, and written
consent was obtained from all patients. Tissues were ob-
tained during surgery on patients undergoing tumor resec-
tion, and the diagnosis of clear cell renal cell carcinoma
was verified post-operatively using histopathology. The
samples were classified according to the criteria provided
by the International Union against Cancer [23].
Cell lines
The cell lines ACHN, 786-O, A-498, CaKi-1 and CaKi-2
were obtained from American Type Culture Collection
(ATCC, Manassas, VA, USA). ACHN and A-498 cells
were cultured in a MEM Alpha medium (Gibco by Life
Technologies, Grand Island, NY, USA), CaKi-1 and
CaKi-2 cells were cultured in a McCoy’s 5A medium
(Gibco by Life Technologies, Grand Island, NY, USA)
and 786-O cells were cultured in a RPMI1640 medium
(Gibco by Life Technologies, Grand Island, NY, USA).
Cell lines were supplemented with 10% FBS (Cultilab, SP,
Brazil), 100 U/mL penicillin (Invitrogen, Grand Island,
NY, USA) and 100 μg/mL streptomycin (Invitrogen, Grand
Island, NY, USA) and were grown in a 37°C, 5% CO2
atmosphere.
GPC3 mRNA expression was analyzed in all cell lines.
Then, representative cell lines, one primary renal carcin-
oma (786-O) and one metastatic renal carcinoma (ACHN),
were chosen to carry out the functional studies.
Plasmid construction
DNA oligonucleotides were chemically synthesized, and ap-
propriate restriction sites were introduced via PCR amplifi-
cation with the following primers: CATCGGTACCATGG
CCGGGACCGTGCG (Forward) and TCGACTCGAGCA
CCAGGAAGAAGAAGCACACCACCG (Reverse). After
PCR purification, products and the pcDNA3.1/V5-HisB
vector were digested by the restriction enzymes KpnI and
XhoI (Uniscience, New England Biolabs, Hitchin, UK).
The products were ligated by T4 DNA ligase (Uniscience,
New England Biolabs, Hitchin, UK). The construct was
confirmed using DNA sequencing.
Transfection
The pcDNA3.1/GPC3 expression vector and pcDNA3.1
(empty vector) were transfected into ACHN and 786-O
cell lines using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s manual.
RNA extraction and qRT-PCR
Total RNA was extracted using TRIzol reagent (Life
Technologies, Grand Island, NY, USA) according to the
manufacturer’s instructions. Approximately 5 μg of total
RNA from each sample was used to synthesize cDNA,
using the High Capacity cDNA Kit (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s
instructions. Real Time PCR was performed using an
ABI Prism 7300 Real Time PCR system and SYBR Green
PCR Core Reagent (Applied Biosystems, Warrington, UK)
following the manufacturer’s protocol. The primer se-
quences were designed using Primer 3 software:
GPC3: GTGCTTTGCCTGGCTACATC (Forward) and
TCCACGAGTTCTTGTCCATTC (Reverse), and GAPDH
(endogenous control): ACCCACTCCTCCACCTTT
GA (Forward) and CTGTTGCTGTAGCCAAATTCGT
(Reverse). In brief, the reaction mixture (20 μL total vol-
ume) contained 25 ng of cDNA, gene-specific forward
and reverse primers for each gene and 10 μL of 2× Quan-
titative SYBR Green PCR Master Mix. The samples were
tested in triplicate.
The relative expression of each specific gene was calcu-
lated using the following formula: R = (E target)ΔCt target
(control - sample)/(E endogenous)ΔCt endogenous (control - sample),
which had been published previously [24]; a cutoff higher
than a 2-fold change was used. The expression of the gene
GPC3 was analyzed in thirty-five clear cell renal cell
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carcinoma samples and the cell lines ACHN, 786-O,
A-498, CaKi-1 and CaKi-2. Two normal renal fresh-frozen
tissue samples were used as the normal reference (control
group). All samples were collected from the renal cortex.
Immunocytochemistry
ACHN and 786-O cells were seeded on coverslips in 24-
well plates. The cells were washed with PBS twice and
fixed with 4% paraformaldehyde for 30 min. Endogenous
peroxidase activity was blocked with 3% hydrogen per-
oxide in methanol for 30 min in the dark and, after wash-
ing in PBS, the non-specific proteins were blocked in 1%
bovine serum albumin (BSA) for 1 h. The cells were incu-
bated at 4°C overnight with rabbit polyclonal anti-GPC3
(5 μg/mL) (ABCAM, Cambridge, UK) diluted in 1% BSA.
After washing, cells were incubated with the biotinylated
secondary antibody (1:200) (Santa Cruz Biotechnology,
California, USA), diluted in 1% BSA for 45 min at 37°C
and then exposed to an HRP-conjugated streptavidin com-
plex (Santa Cruz Biotechnology, CA, USA). The reactions
were visualized using DAB substrate (Dako, Cambridge,
UK) and the slides were counterstained with hematoxylin.
Densitometric analyses of GPC3 were performed with an
Axioshop II Microscope (Zeiss, Germany) using the Soft-
ware Axiovision (Zeiss). For the analyses, eleven different
fields from the coverslips were used and 15 points were
analyzed. The values were obtained on an arbitrary scale.
Colony formation assay
ACHN and 786-O cells transfected with pcDNA3.1/GPC3
and pcDNA3.1 were plated in 6-well plates (300 μL cell
per well) containing 700 μg/mL geneticin (G418, Sigma
Aldrich, St Louis, MO, USA). After 14 days, the colonies
were stained with 0.01% crystal violet. Each experi-
ment was performed in triplicate and in two independent
assays.
Proliferation assay
ACHN and 786-O were seeded into 96-well plates. After
the transfection, 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,
Figure 1 Endogenous GPC3 expression in clear cell renal cell carcinoma. Quantitative mRNA expression of GPC3 was determined via qRT-PCR in
clear cell renal cell carcinoma and renal carcinoma cell lines and shown as fold change (log2) relative to expression in normal renal tissue. A) Expression
(mRNA) of GPC3 in 35 clear cell renal cell carcinoma samples. B) Expression (mRNA) of GPC3 in five clear cell renal cell carcinoma cell lines.
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5-diphenyl-tetrazolium bromide (MTT) (Sigma Aldrich,
St Louis, MO, USA) was added to the wells and incu-
bated for 30 min at 37°C. Then, the MTT was removed,
100 μL of 100% DMSO (Sigma Aldrich, St Louis, MO,
USA) was added to each well and the absorbance was
measured at 562 nm. Each experiment was performed in
triplicate and in two independent assays.
Apoptosis assay
Apoptotic cells were analyzed using a FITC Annexin V
Apoptosis Detection Kit II (BD Biosciences, San Diego,
CA, USA) according to the manufacturer’s instructions.
After transfection, cells were washed twice with PBS and
then resuspended in binding buffer. Next, 5 μL FITC-
Annexin V and 5 μL Propidium Iodide (PI) were added
and the cells were incubated for 15 min in the dark
at room temperature. The cells were analyzed using
an easyCyte 5-HT flow cytometry (Millipore Guava
Technologies, Hayward, USA). Data are from two in-
dependent experiments.
Cell cycle analysis
ACHN and 786-O cells were analyzed 24 h, 48 h and
72 h after the transfection. The cells were washed twice
with PBS and then fixed with ice-cold ethanol (70%).
Next, the samples were stained with 200 μL of Guava Cell
Cycle Reagent (EMD Millipore Corporation, Hayward,
CA, USA), incubated for 30 min at room temperature, and
the analysis was conducted by using the easyCyte 5-HT
flow cytometry (Millipore Guava Technologies, Hayward,
USA). Two independent experiments were performed.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
5 Software. The Mann–Whitney U Test and Wilcoxon
Single Ranks Test were used to compare the protein ex-
pression levels detected through immunohistochemistry.
The comparisons of protein expression levels in cells over-
expressing GPC3 to cells lacking GPC3 were performed
using analysis of variance (ANOVA), with the appropriate
post-hoc test. Group comparisons in the MTT assay were
performed with two-tailed paired Student’s t test. In all
analyses, the differences were considered statistically sig-
nificant when p < 0.05.
Results
Analysis of GPC3 gene expression in clear cell renal cell
carcinoma samples and renal carcinoma cell lines
The GPC3 gene was downregulated in all clear cell renal cell
carcinoma samples, with the exception of one (Figure 1A).
There was no association between GPC3 gene expression
and the clinical data of the clear cell renal cell carcinoma
patients (Table 1). The renal carcinoma cell lines were also
compared with normal renal samples, with fold-change
values for gene expression ranging from −1 to −10.3 in
primary clear cell renal cell carcinoma samples and −7.8
to −14.4 in primary renal carcinoma cell lines (CaKi-2,
A-498 and 786-O) and metastatic renal carcinoma
cell lines (CaKi-1 and ACHN) (Figure 1B). GPC3 expres-
sion was lower in metastatic cell lines than in primary cell
lines. The same observation was made in the case of clear
cell renal cell carcinoma samples, in which GPC3 gene ex-
pression was lower in metastatic samples when compared
with non-metastatic samples. Unfortunately, the number
of metastatic clear cell renal cell carcinoma samples used
in this study was too small to perform a statistical test. To
assess the potential role of GPC3 in this type of cancer, we
performed assays in the 786-O and ACHN renal carcin-
oma cell lines.
We evaluated GPC3 mRNA and protein expression in
the ACHN and 786-O cell lines before and after trans-
fection with the pcDNA3.1/GPC3 expression vector or
an empty vector using qRT-PCR and immunohisto-
chemistry, respectively. GPC3 was upregulated in both
cell lines 48 h after transfection with the pcDNA3.1/
Table 1 Description of clinical data of patients with clear
cell renal cell carcinoma
Variable Number of patients
Gender
Male 19
Female 16
T stage
T1 13
T2 14
T3 7
T4 1
N stage
N0 31
N1 2
N2 1
N3 1
M stage
M0 28
M1 7
Average age in years
Males 57.8
Females 57.1
Smoker
No 30
Yes 5
Alcoholic
No 27
Yes 8
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Figure 2 (See legend on next page.)
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GPC3 vector (Figure 2A). GPC3 protein expression was
increased in the cells transfected with pcDNA3.1/GPC3
vector compared with cells transfected with an empty vec-
tor in both cell lines. GPC3 immunostaining increased sig-
nificantly in the membranes of ACHN and 786-O cells
transfected with the pcDNA3.1/GPC3 vector (p < 0.0001)
(Figures 2B and C).
GPC3 suppresses colony formation
The pcDNA3.1/GPC3 and pcDNA3.1 vectors were trans-
fected in ACHN and 786-O cell lines, and colony formation
ability was assessed after 14 days. Cell lines overexpressing
GPC3 had suppressed growth in the colony formation
assay. GPC3-transfected cells grew significantly fewer col-
onies than cells transfected with an empty vector in both
cell lines (p < 0.01) (Figure 3).
Effect of GPC3 on proliferation in cell lines
Cell proliferation was determined by an MTT assay in
ACHN and 786-O cells overexpressing GPC3 at 24 h,
48 h, 72 h, 96 h and 120 h after transfection. ACHN
cells overexpressing GPC3 experienced a significant re-
duction in cell proliferation compared with ACHN cells
lacking GPC3 expression after 48 h (p < 0.01), 72 h, 96 h
and 120 h (p < 0.0001) (Figure 4A). 786-O cells overex-
pressing GPC3 also had reduced proliferation after 48 h,
72 h, 96 h and 120 h (p < 0.0001) (Figure 4B).
Effect of GPC3 on apoptosis in cell lines
The ability of GPC3 to induce apoptosis was also evalu-
ated. The rate of apoptosis was analyzed in cell lines after
24 h, 48 h and 72 h of transfection with pcDNA3.1/GPC3
and pcDNA3.1 vectors using FITC-Annexin V/PI. No dif-
ference in apoptosis was observed between ACHN and
786-O cells overexpressing or lacking GPC3 at any ana-
lyzed period of time (p > 0.05) (Figure 5).
GPC3 alters cell cycle progression
We then performed cell cycle analysis on ACHN and
786-O cell lines, using flow cytometry 24 h, 48 h and
(See figure on previous page.)
Figure 2 GPC3 expression in renal cell carcinoma cell lines. Restoration of GPC3 expression after transfection with the plasmid pcDNA3.1/GPC3.
ACHN and 786-O cells were transiently transfected with pcDNA3.1 (empty vector) or pcDNA3.1/GPC3 and re-expression of GPC3 was confirmed 48 h
post-transfection by qRT-PCR and immunocytochemistry. A) Quantitative mRNA expression of the GPC3 gene in renal cell carcinoma cell lines after 48 h
of transfection with the pcDNA3.1/GPC3 plasmid is shown as fold change (log2) relative to expression of GPC3 in cell lines after 48 h of transfection
with pcDNA3.1 (empty vector). B) Immunolocalization of the GPC3 protein in ACHN and 786-O cell lines after 48 h of transfection with
the plasmids pcDNA3.1-GPC3 and pcDNA3.1 (empty vector). Bars = 20 μm. C) Densitometry graphic of GPC3 in ACHN and 786-O cell lines
(***p < 0.0001, Mann Whitney test).
Figure 3 Effect of GPC3 on colony formation. The GPC3 gene suppresses the colony formation in ACHN (A) and 786-O (B) cell lines. Tumor
cell proliferation was assessed in vitro. Cells were transiently transfected with pcDNA3.1 (empty vector) or pcDNA3.1/GPC3 and replated 24 h
post-transfection for selection with Geneticin/G418. After 14 days of selection, colonies were stained with Giemsa and counted. Data are
presented as the mean of two independent experiments ± SEM. Group comparisons were carried out using Student’s t test, *p < 0.01.
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Figure 4 Effect of GPC3 on cell proliferation. Cell viability of ACHN and 786-O cells was measured 24 h, 48 h, 72 h, 96 h and 120 h
post-transfection with pcDNA3.1 (empty vector) and pcDNA3.1/GPC3 by MTT assay. Data are presented as the mean of two independent
experiments ± SEM. Group comparisons were carried out using Student’s t test. A) ACHN cells overexpressing GPC3 experienced a significant
reduction in proliferation rate after 48 h (**p < 0.01), 72, 96 and 120 h (***p < 0.0001). B) 786-O overexpressing GPC3 experienced a significant
reduction in proliferation rate after 48 h, 72 h, 96 h and 120 h (*** p <0.0001).
Figure 5 The effect of GPC3 on apoptosis. Apoptosis in ACHN and 786-O cell lines was analyzed using flow cytometry 24 h, 48 h and 72 h
post-transfection. No difference in apoptosis was observed between ACHN and 786-O cell overexpressing and lacking GPC3 at any of the time
points analyzed. Viable cells (Annexin V-/PI-) are located in the bottom left, early apoptotic cells (Annexin V+/PI-) in the bottom right, late apoptotic
cells (Annexin V+/PI+) in the top right and necrotic cells (Annexin V-/ PI+) in the top left quadrants, respectively.
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72 h after transfection with pcDNA3.1/GPC3. The num-
ber of ACHN and 786-O cells overexpressing GPC3 was
evaluated in each phase of the cell cycle and was com-
pared with the number of ACHN and 786-O cells lack-
ing GPC3. There were more ACHN cells overexpressing
GPC3 in the G1 phase (24 h and 48 h, p < 0.001; 72 h,
p < 0.01) and fewer cells overexpressing GPC3 in the
S phase after transfection (48 h and 72 h, p < 0.001)
(Figure 6A). In the 786-O cell line, a higher number
of cells overexpressing GPC3 was observed in the G1
phase after transfection (48 h, p < 0.01; 72 h, p < 0.05)
compared with 786-O cells lacking GPC3 (Figure 6B).
Discussion
Glypican-3 (GPC3) is a member of the family of heparan
sulfate proteoglycans [25,26]. Heparan sulfate proteogly-
cans (HSPGs) have profound effects on both tumor cell
growth kinetics and metastasis formation [27]. HSPGs
have the functional capacity to regulate a myriad of mo-
lecular interactions that induce tumor cell proliferation
and metastasis [28]. Glypican-3 expression is higher in
several tissues, such as the gastrointestinal tract, in hu-
man embryos [29].
In different types of tumors, GPC3 expression and its
carcinogenic role are variable. In some tissues, such as
ovary [19,30], breast [20,31] and lung (adenocarcinoma)
[32], this glypican is downregulated, acting as a tumor
suppressor, whereas in other tumors, it is overexpressed
and functions as an oncoprotein, as observed in liver
[33-35], lung (squamous cell carcinoma) [32,36], melanoma
[18] and embryonal tumors [37]. In a recent study, Gailey
and Bellizzi [38] analyzed GPC3 protein expression in squa-
mous cell carcinoma (SCCs) of diverse anatomic sites and
in invasive urothelial carcinomas from the urinary bladder.
They observed GPC3 staining was present in 17.3% of
156 tumors, including those of the anus (10.0%), cervix
(27.3%), esophagus (28.6%), larynx (30.0%), lung (50.0%),
tongue base/tonsil (12.5%), urinary bladder (12.2%), ven-
tral tongue/floor of mouth (12.5%) and vagina (40.0%).
In the present study, GPC3 expression was down-
regulated in primary clear cell renal cell carcinoma
samples and cell lines. To the best of our knowledge,
this report is the first that has detected downregulation of
the GPC3 gene in clear cell renal cell carcinoma cell lines.
Okon et al. [39] have shown a point of distinction between
GPC3 expression in chromophobe carcinoma and clear
cell renal cell carcinoma; GPC3 expression was upregu-
lated in chromophobe carcinoma and downregulated in
clear cell carcinoma, agreeing with our expression results
in tissue samples and cell lines.
Figure 6 Effect of GPC3 on cell cycle in cell lines. A) ACHN cell cycle histogram. B) 786-O cell cycle histogram. C) The number of ACHN
pcDNA3.1/GPC3 cells was significantly increased during the G1 phase (24 h and 48 h ***p < 0.001, 72 h **p < 0.01, ANOVA) and decreased during
the S phase (48 h and 72 h ***p < 0.001, ANOVA). D) The number of 786-O pcDNA3.1/GPC3 cells was significantly increased in the G1 phase 48 h
(**p < 0.01, ANOVA) and 72 h (*p < 0.05, ANOVA) post-transfection.
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Gailey and Bellizzi [38] also observed an absence of
GPC3 expression in squamous cell carcinomas (SCCs)
from the penis, skin and vulva. As opposed to the results
of this study in clear cell renal cell carcinoma, GPC3
overexpression has emerged as a positive marker in liver
cancer because it is highly expressed in 70-100% of he-
patocellular carcinomas (HCCs) but not in normal adult
liver tissue [33-35]. In addition to being proposed as a
marker for liver tumor diagnosis, GPC3 has also been
evaluated as a target for antibody- and cell-based therap-
ies of HCC [18].
Cell growth was reduced in cells overexpressing GPC3
protein, as measured by colony formation and prolifera-
tion rates 48 h post-transfection in both the 786-O and
ACHN cell lines used in this study. Lin et al. [19] and
Murthy et al. [40] found that GPC3 re-expression in
ovarian cancer cell lines resulted in inhibition of the effi-
ciency of colony formation. Some studies have shown
that GPC3 plays an important role in cell growth and
differentiation [41,42], such as in the case of hepatocel-
lular carcinoma [43]. The data obtained in the present
study suggest that GPC3 inhibits cell proliferation in
clear cell renal cell carcinoma.
Therefore, we studied whether the reduced prolifera-
tion rate in cells overexpressing GPC3 occurs through
the induction of apoptosis or through cell cycle arrest.
Apoptosis, or programmed cell death, is a crucial point
in the carcinogenic process. Cancer cells can overcome
the apoptosis mechanism, and tumor progression con-
tinues [26,44]. We observed that most cells, whether
overexpressing or lacking GPC3, were viable at all time
points in ACHN and 786-O cell lines. Our results sug-
gest that cells overexpressing GPC3 in renal cell carcin-
oma do not induce apoptosis; therefore, we hypothesized
that the inhibition of cell proliferation in renal carcin-
oma cells might occur due to cell cycle arrest.
To verify whether GPC3 overexpression arrests the cell
cycle in renal cell carcinoma, we used flow cytometry to
perform cell cycle analysis. The observed growth-repressive
effect of GPC3 overexpressing cells was reflected by their
arrest in the G1 cell cycle phase, which caused these cells
to proliferate less in both cell lines. In this study, we ob-
served changes in cell proliferation through the use of
MTT assays in the ACHN cell line 48 h post-transfection.
Using flow cytometry, we were able to identify changes in
the cell cycle and, consequently, in cell proliferation 24 h
after transfection for the same cell line. This difference
is likely due to the increased sensitivity of the flow cy-
tometry methodology to detecting changes in cell cycle
and proliferation compared with the MTT assay. One
previous study demonstrated that inhibiting GPC3 ex-
pression released hepatocyte carcinoma cells from G1
arrest and thus modulated cell cycle progression in this
type of cancer [45].
Moreover, cell surface HSPGs inhibit invasion by pro-
moting tight cell–cell and cell–extracellular matrix
(ECM) adhesion. Previous studies documented dimin-
ished quantity and quality of heparan sulfate isolated
from transformed cells compared with normal cells [46].
This alteration in heparan sulfate accompanies a reduc-
tion in the adhesive capacity of transformed cells. Low
levels of cell surface heparan sulfates also correlate with
high metastatic activity in melanomas [47,48]. Further-
more, GPC3 downregulation was more significant in inva-
sive areas, a result which further supports an inhibitory
role for GPC3 in tumor progression in hepatocellular
carcinomas [49]. Enhanced glypican-3 expression differen-
tiates the majority of hepatocellular carcinomas from be-
nign hepatic disorders. Conversely, glypican-3 expression
is decreased in human breast cancers, and ectopic expres-
sion of GPC3 inhibits growth of breast cancer cell lines
[20]. Additionally, glypican-3 was associated with the
inhibition of invasion and metastasis of a mammary car-
cinoma cell line in vivo [50]. Thus, cells with normal epi-
thelial morphology exhibit retention of cell surface HSPGs
and tight attachment to the extracellular matrix. Cells that
are beginning to invade exhibit reduced adhesion to the
ECM, loss of epithelial morphology, and diminished levels
of HSPG expression, whereas deeply invading cells com-
pletely lose HSPG expression [28].
Conclusions
GPC3 gene expression is downregulated in primary clear
cell renal cell carcinoma, and GPC3 protein overexpres-
sion in clear cell renal cell carcinoma cell lines arrests
cells during the G1 phase of the cell cycle, consequently
reducing the proliferation rate. These results suggest
that GPC3 acts as a tumor suppressor in clear cell renal
cell carcinoma.
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